Survival outcomes after toxicity-related dose modification of 5-fluorouracil, leucovorin and oxalipatin (FOLFOX) in stage III, resected colorectal cancer patients

被引：0
|
作者：
Ha, F. J. [1 ]
Aksakal, G. [1 ]
Chong, G. [1 ]
机构：
[1] Austin Hosp, Dept Med Oncol, Olivia Newton John Canc Res Inst, Melbourne, Vic, Australia
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
210P
引用
收藏
页数：1
相关论文
共 50 条
  • [41] A prospective validation pharmacogenomic study in the adjuvant setting of colorectal cancer patients treated with the 5-fluorouracil/leucovorin/oxaliplatin (FOLFOX4) regimen
    E Cecchin
    M D'Andrea
    S Lonardi
    C Zanusso
    N Pella
    D Errante
    E De Mattia
    J Polesel
    F Innocenti
    G Toffoli
    The Pharmacogenomics Journal, 2013, 13 : 403 - 409
  • [42] Oral capecitabine versus intravenous 5-fluorouracil and leucovorin in stage II and III colorectal cancer: The Bendigo experience 2007-2017
    Cui, Wanyuan
    Freeman, Samantha
    Malsem, Eve
    Luu, Victor
    Ng, Say
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2018, 14 : 93 - 93
  • [43] Raltitrexed (Tomudex) administration in patients with relapsed metastatic colorectal cancer after weekly irinotecan/5-Fluorouracil/Leucovorin chemotherapy
    Nicolas Tsavaris
    Christos Kosmas
    Maria Vadiaka
    Christos Koufos
    BMC Cancer, 2
  • [44] Phase II study of a weekly 8-hour 5-fluorouracil and leucovorin infusion for patients with advanced colorectal cancer: Dose adjusted according to its toxicity
    Yang, TS
    Hsu, KC
    Wang, HM
    Lin, YC
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2001, 31 (12) : 610 - 615
  • [45] Raltitrexed (Tomudex) administration in patients with relapsed metastatic colorectal cancer after weekly irinotecan/5-Fluorouracil/Leucovorin chemotherapy
    Tsavaris, N
    Kosmas, C
    Vadiaka, M
    Koufos, C
    BMC CANCER, 2002, 2 (1)
  • [46] Oxaliplatin with high-dose leucovorin and infusional 5-fluorouracil in irinotecan-pretreated patients with advanced colorectal cancer (ACC)
    Kouroussis, C
    Souglakos, J
    Mavroudis, D
    Papadouris, S
    Kakolyris, S
    Agelaki, S
    Kalbakis, K
    Panopoulos, C
    Vardakis, N
    Sarra, E
    Georgoulias, V
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2002, 25 (06): : 627 - 631
  • [47] A Phase II trial of weekly infusional 5-fluorouracil in combination with low-dose leucovorin in patients with advanced colorectal cancer
    Haas, NB
    Schilder, RJ
    Nash, S
    Weiner, LM
    Catalano, RC
    Ozols, RF
    ODwyer, PJ
    INVESTIGATIONAL NEW DRUGS, 1995, 13 (03) : 229 - 233
  • [48] Biweekly bolus 5-fluorouracil and leucovorin plus oxaliplatin in pretreated patients with advanced colorectal cancer: a dose-finding study
    Yang, TS
    Chen, JS
    Tang, R
    Chiang, JM
    Hsieh, PS
    Yeh, CY
    Changchien, CR
    ANTI-CANCER DRUGS, 2003, 14 (02) : 145 - 151
  • [49] Celecoxib in addition to standard adjuvant therapy with 5-fluorouracil, leucovorin, oxaliplatin (FOLFOX) in stage III colon cancer: Results from CALGB/SWOG 80702.
    Meyerhardt, Jeffrey A.
    Shi, Qian
    Fuchs, Charles S.
    Niedzwiecki, Donna
    Zemla, Tyler J.
    Kumthekar, Priya
    Guthrie, Katherine A.
    Couture, Felix
    Kuebler, J. Phillip
    Bendell, Johanna C.
    Kumar, Pankaj
    Lewis, DeQuincy Andrew
    Tan, Benjamin R.
    Bertagnolli, Monica M.
    Grothey, Axel
    Hochster, Howard S.
    Goldberg, Richard M.
    Venook, Alan P.
    Blanke, Charles David
    Shields, Anthony Frank
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [50] A phase I study of vorinostat (suberoylanilide hydroxamic acid, SAHA) in combination with 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX) in patients with advanced colorectal cancer (CRC).
    Fakih, M. G.
    Pendyala, L.
    Toth, K.
    Creaven, P.
    Soehnlein, N.
    Litwin, A.
    Trump, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 168S - 168S
12345